Carisoprodol and Meprobamate, Urine, Quantitative

Casandra

Casandra Test Code AR24531Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 2012219CPT Codes 0480, 80369

Carisoprodol and Meprobamate, Urine, Quantitative

Also known as: CARIS U

Clinical Use

Order Test

Use

The Carisoprodol and Meprobamate, Urine, Quantitative test is utilized predominantly for confirming presumptive drug screening results, assessing compliance, or monitoring therapeutic doses. It aids in the detection of both Carisoprodol and its metabolite Meprobamate in the urine. This quantification can be helpful in managing patient care and tailoring individual treatment plans, especially in the context of substance misuse or therapeutic drug management. Its design is for clinical purposes only, implying that it is not suitable or validated for forensic purposes.

Special Instructions

This test is specifically administered following presumptive drug screening results. For general screening purposes, the Carisoprodol Urine with Reflex to Quantitation (2012278) is recommended. The presence of metabolite(s) without the parent drug could signify drug use within the preceding week. The test is crucial in providing insights into compliance, timing of specimen collection, drug absorption, and potential specimen adulteration or dilution.

Limitations

The absence of anticipated drugs or drug metabolites can signal non-compliance, improper specimen collection timing relative to drug administration, inadequate drug absorption, or possible sample dilution/adulteration. The test's validity hinges on concentrations exceeding the specified cutoff to be reported as positive. It is not applicable for forensic use. Analytical or technical limitations inherent to the assay could restrict its interpretive capacity, which necessitates direct laboratory consultation for further clarification on interpretive questions.

Test Details

New York Approved